Objectives: This study aimed to investigate the validity of gastric cancer surgery in elderly patients. Methods: A total of 544 patients who underwent elective gastrectomy for gastric cancer were divided into an elderly group (age ≥75 years, n = 171) and a control group (age <75 years, n = 373). The clinicopathological data of the patients were reviewed. Results: The overall morbidity rate (26.3 vs. 16.1%, p = 0.005) and the incidence rate of anastomotic leakage (6.4 vs. 1.6%, p = 0.003) were significantly higher in the elderly group. The proportion of patients who had severe complications (≥grade IIIa) was relatively higher in the elderly group (10.5 vs. 5.7%); however, the difference was not significant (p = 0.074). A stage-matched survival analysis revealed no significant differences between the groups (stage I: p = 0.978; stage II: p = 0.964; stage III: p = 0.199). For the pathological stages II and III, the overall survival of the patients in the elderly group who received adjuvant chemotherapy for >3 months was significantly better than that of the patients who received it for ≤3 months or did not receive it (p = 0.023). Conclusions: An aggressive treatment strategy should be adopted in selected elderly patients with gastric cancer.

Keywords:
Gastric cancer, Surgery, Elderly, Adjuvant chemotherapy
1.
Editorial Board of the Cancer Statistics in Japan: Cancer Statistics in Japan 2016. Tokyo, Foundation for Promotion of Cancer Research, 2016, pp 15-23, 125.
2.
United Nations, Department of Economic and Social Affairs, Population Division (2015): World Population Prospects: The 2015 Revision, Key Findings and Advance Tables. Working Paper No. ESA/P/WP.241, pp 27-31.
3.
Statistics Bureau, Ministry of Internal Affairs and Communications: Population Estimates by Age (5-Year Age Group) and Sex. http://www.stat.go.jp/english/data/jinsui/tsuki/index.htm (accessed May 26, 2017).
4.
Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K: Frailty in elderly people. Lancet 2013;381:752-762.
5.
Dindo D, Demartines N, Clavien PA: Classification of surgical complications: a new proposal with evaluation in a cohort of 6,336 patients and results of a survey. Ann Surg 2004;240:205-213.
6.
Japanese Gastric Cancer Association: Japanese classification of gastric carcinoma, 3rd English edition. Gastric Cancer 2011;14:101-112.
7.
Japanese Gastric Cancer Association: Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 2017;20:1-19.
8.
Lee KG, Lee HJ, Yang JY, Oh SY, Bard S, Suh YS, Kong SH, Yang HK: Risk factors associated with complication following gastrectomy for gastric cancer: retrospective analysis of prospectively collected data based on the Clavien-Dindo system. J Gastrointest Surg 2014;18:1269-1277.
9.
Persiani R, Antonacci V, Biondi A, Rausei S, La Greca A, Zoccali M, Ciccoritti L, D'Ugo D: Determinants of surgical morbidity in gastric cancer treatment. J Am Coll Surg 2008;207:13-19.
10.
Kitano Y, Iwatsuki M, Kurashige J, Kuroda D, Kosumi K, Baba Y, Sakamoto Y, Miyamoto Y, Yoshida N, Haga Y, Baba H: Estimation of Physiologic Ability and Surgical Stress (E-PASS) versus modified E-PASS for prediction of postoperative complications in elderly patients who undergo gastrectomy for gastric cancer. Int J Clin Oncol 2017;22:80-87.
11.
Takeshita H, Ichikawa D, Komatsu S, Kubota T, Okamoto K, Shiozaki A, Fujiwara H, Otsuji E: Surgical outcomes of gastrectomy for elderly patients with gastric cancer. World J Surg 2013;37:2891-2898.
12.
Cheng H, Hsiao CW, Clymer JW, Schwiers ML, Tibensky BN, Patel L, Ferko NC, Chekan E: Gastrectomy and D2 lymphadenectomy for gastric cancer: a meta-analysis comparing the harmonic scalpel to conventional techniques. Int J Surg Oncol 2015;2015:397260.
13.
Zhou H, Yi W, Zhang J, Wang W, Wang Y, Gao W, Hu Z: Short- and long-term outcomes of LigaSure versus conventional surgery for curative gastric cancer resection: a matched pair analysis. Gastric Cancer 2015;18:843-849.
14.
Liang YX, Deng JY, Guo HH, Ding XW, Wang XN, Wang BG, Zhang L, Liang H: Characteristics and prognosis of gastric cancer in patients aged ≥70 years. World J Gastroenterol 2013;19:6568-6578.
15.
Sasada S, Ikeda Y, Saitsu H, Saku M: Characteristics of gastric cancer in patients over 80-years-old. Hepatogastroenterology 2008;55:1931-1934.
16.
Endo S, Dousei T, Yoshikawa Y, Hatanaka N, Kamiike W, Nishijima J: Prognosis of gastric carcinoma patients aged 85 years or older who underwent surgery or who received best supportive care only. Int J Clin Oncol 2013;18:1014-1019.
17.
Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y: Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011;29:4387-4393.
18.
Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, Lee JI, Shin DB, Ji J, Chen JS, Lim Y, Ha S, Bang YJ: Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:1389-1396.
19.
Sun DS, Jeon EK, Won HS, Park JC, Shim BY, Park SY, Hong YS, Kim HK, Ko YH: Outcomes in elderly patients treated with a single-agent or combination regimen as first-line chemotherapy for recurrent or metastatic gastric cancer. Gastric Cancer 2015;18:644-652.
20.
Koizumi W, Akiya T, Sato A, Sakuyama T, Sasaki E, Tomidokoro T, Hamada T, Fujimori M, Kikuchi Y, Shimada K, Mine T, Yamaguchi K, Sasaki T, Kurihara M: Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study. Cancer Chemother Pharmacol 2010;65:1093-1099.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.